Table. Participant Characteristics.
| Participant immunological history, No. | Vaccine (in chronological order) | Age, mean (range), y | Sex, men/women |
|---|---|---|---|
| 2 Doses (n = 10) | |||
| 6 | 2 BNT162b2 | 42.5 (23-56) | 3/7 |
| 3 | 2 mRNA-1273 | ||
| 1 | 2 ChAdOx1-S | ||
| 3 Doses of mRNA (n = 15) | |||
| 14 | 3 BNT162b2 | 52 (26-60) | 5/10 |
| 1 | 2 BNT162b2 + 1 mRNA-1273 | ||
| Heterologous (n = 11) | |||
| 3 | 2 ChAdOx1-S+ 1 mRNA-1273 | 53 (26-62) | 3/8 |
| 6 | 2 ChAdOx1-S+ 1 BNT162b2 | ||
| 2 | 1 Ad26.COV2.S + 1 BNT162b2 | ||
| COVID-19 then Vaccine (n = 12) | |||
| 7 | 2 BNT162b2 | 53.5 (22-60) | 8/4 |
| 2 | 3 BNT162b2 | ||
| 1 | 1 Ad26.COV2.S | ||
| 1 | 1 mRNA-1273 | ||
| 1 | 1 Ad26.COV2.S + 1 mRNA-1273 | ||
| Vaccine then COVID-19 (n = 13) | |||
| 9 | 2 BNT162b2 | 37 (21-54) | 4/9 |
| 1 | 1 Ad26.COV2.S | ||
| 1 | 2 ChAdOx1-S+ 1 mRNA-1273 | ||
| 1a | 2 ChAdOx1-S | ||
| 1a | 2 BNT162b2 |
a
Infected with the SARS-CoV-2 Omicron variant.